MedTrace Logo

An Investigation of Tendoncel, a Novel Topical Platelet Lysate Gel, in the Treatment of Lateral Epicondylitis

NCT03811145 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-12

No results posted yet for this study

Summary

Current treatments for lateral epicondylitis include: rest, behaviour modification and physiotherapy, anti-inflammatory medication - both steroidal and non-steroidal, and surgery. Current experimental therapies include muscle relaxants to reduce muscle tone and force on the epicondyle, laser therapy to stimulate collagen production, and blood based therapies including the injection of autologous blood and protein rich plasma.

Cell Therapy Ltd (trading as Celixir) has developed a regenerative gel that combines isolated allogeneic platelet growth factors and a cellulose-derivative gel.

Conditions

  • Lateral Epicondylitis

Interventions

BIOLOGICAL

Tendoncel

Platelet lysate gel

OTHER

Placebo control gel

Placebo control gel

Sponsors & Collaborators

  • George Papanicolaou Hospital

    collaborator OTHER

  • Cell Therapy Ltd.

    lead INDUSTRY

Principal Investigators

  • Givissis Panagiotis, MD · Aristotle University of Thessaloniki, General Hospital of Papanikolaou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03811145 on ClinicalTrials.gov